ERSP recommends Perricone modify ads
This article was originally published in The Tan Sheet
Executive SummaryPerricone MD will clarify Cold Plasma Skin Cream claims that are based on consumer perceptions rather than "clinical proof," as recommended by the Electronic Retailing Self-Regulation Program. For example, a four-week, blinded consumer perception study in which 202 subjects evaluated the product after the first and fourth weeks, did not support claims that "skin will look lifted and firmer in minutes." Perricone based the claim on 85 percent of study participants saying Cold Plasma imparted "instant results." But ERSP said the product's capacity to firm and lift were not addressed in the survey question. The watchdog also said the firm could not assume that consumers understood the word "instant" to mean "within minutes." While Perricone disagrees with ERSP, it says it will take the panel's guidance into consideration
You may also be interested in...
Having had a very fruitful year in terms of regulatory approvals, the Swiss major will reveal how successful its new products have been commercially. Of particular interest will be the performance of eye drug Beovu as it takes on Bayer's rival Eylea.
Executives On The Move: New Picks For Finance Posts At Cambrex And Editas Medicine, And Zimmer Biomet Fills Communications Spot
Gene-editing company Editas Medicine appoints a new CFO, while Affimed and NexImmune bring new chief medical officers on board.
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.